Molina Healthcare Company Profile (NYSE:MOH)

Molina Healthcare trades on the New York Stock Exchange (NYSE) under the ticker symbol "MOH."

Molina Healthcare Inc (NYSE:MOH) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.01) EPS for the quarter, missing analysts' consensus estimates of $0.86 by $0.87. The company had revenue of $5 billion for the quarter, compared to analyst estimates of $4.88 billion. Molina Healthcare had a negative net margin of 1.07% and a positive return on equity of 16.10%. Molina Healthcare's quarterly revenue was up 14.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.67 EPS. View Molina Healthcare's Earnings History.

Molina Healthcare is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Molina Healthcare.

14 brokerages have issued 12 month price targets for Molina Healthcare's shares. Their forecasts range from $48.00 to $72.00. On average, they expect Molina Healthcare's share price to reach $62.50 in the next twelve months. View Analyst Ratings for Molina Healthcare.

Here are some recent quotes from research analysts about Molina Healthcare stock:

• 1. According to Zacks Investment Research, "Molina Healthcare’s shares have underperformed the industry in last one year. The company suffers from rising medical care costs along with acute dependence on debt financing that have resulted in higher interest expenses draining the bottom line. Following its lackluster second-quarter 2017 results, the company also withdrew its 2017 guidance. It has seen the Zacks Consensus Estimate for the 2018 earnings being revised downward in last 60 days." (10/3/2017)
• 2. Morgan Stanley analysts commented, "extreme makeover," according to analysts at Morgan Stanley. The firm's Zack Sopcak upgrades Molina Healthcare's stock rating from Underweight all the way to Overweight with a price target boosted from $65 to $68.Shares of Molina Healthcare have gained more than 20 percent since the company parted ways with its CEO and chief financial officer in May of 2017, Sopcak noted. The management shuffle is viewed as a "much needed overhaul" for the "less efficient" player in the Medicaid space (see Sopcak's track record here).However, Molina Healthcare's stock has given back a lot of its gains since early June but this isn't necessarily justified since the company communicated a clear cost cutting plan and strategy, Sopcak continued. Specifically, management detailed a path toward $200 million in savings by the end of the year and $300 to $400 million by the end of 2018, mostly due to staffing reductions, exiting non-strategic ACA-marketplace regions and implementing tighter physician networks and contracts.Perhaps more important to Molina Healthcare's stock, the company's strategy moving forward also limits downside. In fact, even if the company doesn't fully meet its financial targets its strategy will at the very least result in a "more-right sized structure" (8/17/2017)
• 3. Cowen and Company analysts commented, "We are initiating at Market Perform with a $48 PT given potential long-term headwinds to MOH's core Medicaid business. The Republican ACA repeal plan proposes to reduce Medicaid funding and roll back Medicaid expansion ' though we are still early in the process. Individual losses could be a near-term headwind. MOH's exposure to an uncertain political environment keeps us on the sidelines for now." (3/15/2017)
• 4. Jefferies Group LLC analysts commented, "We stepped aside in Dec for Medicaid Expansion and Exchange (HIX) concerns. Though we were in the right zip code, we clearly hadn't zeroed in on the 4Q operational underperformance at this "address." HIX losses in 4Q account for $1.47 of the loss. Out of period items are another $0.70 drag. Thus, we estimate an adjusted EPS power number of ~$0.63. Annualizing that (~$2.50) falls 30% + below consensus. The after hours 14% sell-off is probably too optimistic. Bridge to EPS Power. The company's 4Q16 adjusted EPS loss was $1.54. That reflected $1.47 of EPS drag from HIX, consisting of a $0.34 PDR for 2017 and $1.13 for other underperformance largely driven by higher Risk Adjustment payments. MOH also was adversely impacted by $0.70 of out of period premium and provider adjustments (includes $0.29 for 2014-15 and $0.41 for 1Q16-3Q16), which is alarming given how far back these adjustments cover. Those add backs result in adjusted 4Q EPS power of $0.63, which was well below the Street's $0.75." (2/16/2017)

Some companies that are related to Molina Healthcare include TESARO (TSRO), Bio-Rad Laboratories (BIO), BIOVERATIV INC (BIVV), Icon Plc (ICLR), bluebird bio (BLUE), Dr. Reddy's Laboratories Ltd (RDY), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Neurocrine Biosciences (NBIX), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), Galapagos NV (GLPG), PRA Health Sciences (PRAH), Hill-Rom Holdings (HRC), Envision Healthcare Corporation (EVHC), Juno Therapeutics (JUNO), Premier (PINC) and Medidata Solutions (MDSO).

Molina Healthcare's management team includes the folowing people:

• Dale B. Wolf, Chairman of the Board
• Joseph W. White CPA, Interim President, Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer
• Terry P. Bayer, Chief Operating Officer
• Jeffrey D. Barlow J.D., Chief Legal Officer, Corporate Secretary
• Ronna E. Romney, Lead Independent Director
• John C. Molina J.D., Director
• Joseph Mario Molina M.D., Director
• Garrey E. Carruthers Ph.D., Independent Director
• Charles Z. Fedak CPA, Independent Director

Shares of Molina Healthcare can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Molina Healthcare stock can currently be purchased for approximately $59.86.